Targeting epigenetics and ferroptosis in DLBCL

should encourage us to better address 2 needs in CLL trials enrolling older patients: First, geriatric burden and frailty of trial participants at baseline should be captured and described not only by age, ECOG PS, and the Cumulative Illness Rating Scale, but also by GA.Second, in addition to common hematological end points, such as response, adverse events, and survival, the geriatric burden and frailty should be analyzed by longitudinal GA measurements and reported as an outcome of the treatment.If this is omitted, highly relevant benefits of modern drug-based CLL therapy for older patients might not be recognized.The reported results of HOVON139/GiVe on GA also provide a rationale for integrating GA into routine care.This can help to identify older patients at increased risk of nonhematological toxicity and, specifically, to provide guidance when planning targeted drug therapy for CLL with Ven-O.